Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

SY-5609 Under Investigation With Atezolizumab in Colorectal Cancer Subsets

August 25th 2021

The highly selective and potent CDK7 inhibitor SY-5609 is being tested in combination with atezolizumab in patients with molecularly defined subsets of colorectal cancer, as one of the cohorts of the ongoing, phase 1/1b INTRINSIC trial.

Novel Approaches Under Study for Metastatic CRC

August 24th 2021

John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.

Treating Metastatic CRC With TKI/I-O Combinations

August 24th 2021

The rationale for continuing to study the combination of immunotherapies with novel tyrosine kinase inhibitors in metastatic colorectal cancer.

Dr. Fakih on Efficacy With Regorafenib Plus Nivolumab in Metastatic CRC

August 23rd 2021

Marwan Fakih, MD, discusses efficacy reported with regorafenib plus nivolumab in patients with mismatch repair–proficient and microsatellite stable metastatic colorectal cancer.

Average Cumulative Relative Adjuvant Chemo Dose Linked With Survival in CRC

August 17th 2021

Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.

Metastatic CRC: Pembrolizumab Plus Lenvatinib

August 17th 2021

Implications for using the combination of pembrolizumab and lenvatinib to treat patients with metastatic colorectal cancer based on updated data from the LEAP-005 study.

Metastatic CRC: Nivolumab Plus Regorafenib

August 17th 2021

Considerations for treating patients with metastatic colorectal cancer with the combination of nivolumab and regorafenib based on preliminary data.

Early Screening for Colorectal Neoplasia and Cancer Is Critical Among Younger Individuals

August 11th 2021

Steven H. Itzkowitz, MD, discusses the importance of screening for CRC in younger adults, the results of the database analysis, and strategies for implementing early messaging in the community setting for this population.

Topical BRAF Inhibitor, LUT014, Dosed in First US Patients With mCRC for Acneiform Lesions

August 10th 2021

The first participants from the United States have been dosed with LUT014, a novel, topical BRAF inhibitor in a phase 2 trial that is evaluating the agent in patients with metastatic colorectal cancer who have developed dose-limiting acneiform lesions following treatment with an EGFR inhibitor.

MSI-H Metastatic CRC: Chemo Vs I-O Debated

August 10th 2021

Drs. John L. Marshall, Marwan G. Fakih, and Joleen M. Hubbard, describe the current role of chemotherapy for frontline metastatic colorectal cancer based on novel treatment advances.

Dr. Jones on the Importance of Immune Checkpoint Inhibitors in CRC

August 10th 2021

Jeremy C. Jones, MD, discusses key lessons learned from the phase 3 KEYNOTE-177 trial.

MSI-H Metastatic CRC: Frontline Immunotherapy

August 10th 2021

Considerations for frontline immunotherapy for patients with microsatellite instability high metastatic colorectal cancer based on data from the KEYNOTE-177 and CheckMate 142 studies.

Dr. Cohen on the Standardization of Triplet Chemotherapy in CRC

August 4th 2021

Stacey A. Cohen, MD, discusses the standardization of triplet-based chemotherapy regimens in colorectal cancer.

Metastatic CRC: Frontline Therapy With EGFR Inhibitors

August 3rd 2021

Mayo Clinic’s Joleen M. Hubbard, MD, interprets data recently presented on the use of EGFR inhibitors as frontline therapy for appropriate patients with metastatic colorectal cancer.

MSS Metastatic CRC: First-Line Treatment Selection

August 3rd 2021

Tumor characteristics, patient factors, and supporting data that affect frontline treatment decisions for patients with microsatellite stable (MSS) metastatic colorectal cancer.

Triplet Combination Demonstrates Promise for Frontline Treatment of BRAF V600E–mutant CRC

July 28th 2021

Doublet and triplet chemotherapy-based therapies are standard treatment options for patients with BRAF V600–mutant metastatic colorectal cancer.

Anti-EGFR/Chemo Combos Allow for Tailored Approach in mCRC

July 28th 2021

Ardaman Shergill, MD, discussed the use of EGFR inhibitors in metastatic colorectal cancer and advantages of expanded dosing indications.

Biweekly Cetuximab Offers a Convenient Dosing Option in mCRC

July 27th 2021

Richard Kim, MD, discusses the utility of EGFR inhibitors in patients with RAS wild-type colorectal cancer, the convenience of biweekly dosing with cetuximab, recommendations for managing EGFR inhibitor–related treatment-related adverse effects, and novel combinations on the horizon.

Molecular Markers and Tumor Sidedness in Metastatic CRC

July 27th 2021

Metastatic colorectal cancer (CRC) experts discuss tumor sidedness and their current use of next-generation sequencing panels to assess patients and guide treatment decisions.

Treatment Gaps for Patients With Metastatic CRC

July 27th 2021

Reactions to the increase in prevalence of metastatic colorectal cancer (CRC) among a younger patient population despite treatment advances.